well, i am very impressed. i thought you would hear me because it was loud. that you were able to do that. so, how are you feeling? better than i deserve. yeah? uh, we have been talking about a lot about the vaccines, about vaccine misinformation. about all the about fda approval and on and on. i have been doing some research on that and i think a lot i think, listen, it s important, obviously, that the fda approves the vaccines. but everything that i am reading saying that the fda approval doesn t really matter, that much. what matters is the efficacy. and that the emergency-use authorization actually came through the fda. and that, what matters is efficacy, and people put too much it s actually become a talking point. people are putting too much emphasis on fda approval, when the fda approval, really, doesn t matter as much as people think. what matters is the efficacy and the vaccines are effective. 49% of people, who haven t been vaccinated, say it
Apollon Wealth Management LLC raised its stake in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 4.7% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 77,741 shares of the biopharmaceutical company’s stock after purchasing an additional 3,525 shares during the period. Apollon Wealth Management LLC’s holdings in Bristol-Myers […]
Maryland State Retirement & Pension System lessened its position in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 2.1% during the fourth quarter, HoldingsChannel.com reports. The fund owned 158,516 shares of the biopharmaceutical company’s stock after selling 3,406 shares during the period. Maryland State Retirement & Pension System’s holdings in Bristol-Myers Squibb were worth […]
Apollon Wealth Management LLC boosted its holdings in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 4.7% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 77,741 shares of the biopharmaceutical company’s stock after buying an additional 3,525 shares during the quarter. Apollon Wealth Management LLC’s holdings in Bristol-Myers Squibb were worth $3,989,000 […]
Machina Capital S.A.S. boosted its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 8.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,912 shares of the biopharmaceutical company’s stock after buying an additional 885 shares during the quarter. Machina Capital […]